Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News MannKind Corp MNKD

Healthcare Biotechnology
MannKind Corporation is a biopharmaceutical company. It is focused on the development and commercialization of inhaled therapeutic products for patients with endocrine and orphan lung diseases. Its technologies include Technosphere dry-powder formulations and Dreamboat inhalation devices, which offers delivery of medicines to the deep lung where they can exert an effect locally or enter the... see more

Recent & Breaking News (NDAQ:MNKD)

MannKind Corporation to Present at the J.P. Morgan 2017 Healthcare Conference

GlobeNewswire January 5, 2017

MannKind Announces Key Addition to Its Executive Management Ranks

GlobeNewswire January 4, 2017

MannKind Receives $1 Million Milestone From RLS

GlobeNewswire January 3, 2017

How These Biotech Stocks are Faring? -- Celgene, Sarepta Therapeutics, MannKind and Amgen

PR Newswire December 6, 2016

MannKind, Sanofi Reach Agreement on AFREZZA; Sanofi to Purchase $10.2M Worth of Insulin from MannKind

Benzinga.com  November 9, 2016

MannKind and Sanofi Reach Agreement on AFREZZA®

GlobeNewswire November 9, 2016

MannKind Corporation Reports 2016 Third Quarter Financial Results

GlobeNewswire November 9, 2016

MannKind Corporation to Hold 2016 Third Quarter Financial Results Conference Call on November 9, 2016

GlobeNewswire November 1, 2016

Research Reports on Biotech Equities -- Celgene, Sarepta Therapeutics, Threshold Pharma, and MannKind

PR Newswire October 6, 2016

Stocks Hitting 52-Week Lows

Benzinga.com  September 26, 2016

MannKind Corporation to Present at the Rodman & Renshaw 18th Annual Global Investment Conference

GlobeNewswire September 2, 2016

MannKind Is 'Making Progress' On Its Alternative To Mylan's EpiPen, Report Says

Benzinga.com  August 30, 2016

Securities Class Action Against MannKind Dismissed

GlobeNewswire August 25, 2016

Research Report on Biotech Equities -- Celgene, Sarepta Therapeutics, MannKind, and Opko Health

PR Newswire August 24, 2016

MannKind Corporation Reports 2016 Second Quarter Financial Results

GlobeNewswire August 8, 2016

MannKind Corporation to Hold 2016 Second Quarter Financial Results Conference Call on August 8, 2016

GlobeNewswire August 1, 2016

Mannkind Assumes Responsibility for Distribution of Afrezza® and Launches Patient Reimbursement and Adherence Support Programs

GlobeNewswire August 1, 2016

MannKind Corporation to Present at Cantor Fitzgerald’s 2nd Annual Healthcare Conference

GlobeNewswire July 8, 2016

Biotechnology Equities at a Glance -- MannKind, bluebird bio, OncoGenex Pharma, and Hevat Biologics

PR Newswire June 27, 2016

MannKind Announces Late-Breaking Data Reinforcing Faster Onset and Shorter Duration of Action Compared to Mealtime Insulins

GlobeNewswire June 12, 2016